论文部分内容阅读
目的比较复方甲氧那明与二羟丙茶碱用于慢性阻塞性肺疾病稳定期患者的临床疗效。方法选取201 1年1 2月~20 1 2年6月在我院就诊的慢性阻塞性肺疾病(C O P D)稳定期患者60例,入选患者均符合2007年中华医学会呼吸学病分会制定的C O P D诊断标准。患者随机分为两组,每组30例。两组患者均采用家庭氧疗(6h/d)、呼吸肌功能训练、适度体育锻炼、支气管扩张剂等常规治疗。观察组在常规治疗基础上加用复方甲氧那明胶囊,3次/d口服,每次25mg;对照组在常规治疗基础上加用二羟丙茶碱片,3次/d口服,每次20 0mg。比较治疗前,治疗3个月和6个月时的C AT问卷和mMRC量表得分。结果治疗前两组患者C AT问卷和mMRC量表得分差异均无统计学意义(P>0.05)。治疗3个月和6个月时,两组患者的C AT问卷和mMRC量表得分均显著低于治疗前差异有统计学意义(P<0.0 5),且观察组患者下降幅度更大(P<0.0 5)。结论在治疗C O P D稳定期患者的联合用药方案中,使用复方甲氧那明效果更为显著,值得临床推广。
Objective To compare the clinical efficacy of the combination of metoprolol and dihydroxy-theophylline in patients with stable chronic obstructive pulmonary disease. Methods Sixty patients with chronic obstructive pulmonary disease (COPD) who were treated in our hospital from January 2011 to January 2012 were enrolled in this study. All patients were eligible for COPD established by the Respiratory Diseases Branch of Chinese Medical Association in 2007 Diagnostic criteria. Patients were randomly divided into two groups, 30 cases in each group. Both groups were treated with routine oxygen therapy (6h / d), respiratory muscle function training, moderate physical exercise and bronchodilator. The observation group was treated with compound triamcinolone acetonide on the basis of routine treatment, orally for 3 times / d, each time being 25 mg. The control group was treated with dipyridamole 3 times daily on the basis of routine treatment, 20 0mg. C AT questionnaires and mMRC scale scores were compared before treatment, 3 months and 6 months after treatment. Results There was no significant difference between the two groups before treatment C AT questionnaire and mMRC scale scores (P> 0.05). At 3 and 6 months of treatment, the C AT questionnaire and mMRC scale scores were significantly lower in both groups than before treatment (P <0.0 5), and the decline in the observation group was greater (P <0.0 5). Conclusions The combination of metoprolol is more effective in the combination regimen in the stable COPD patients, which is worthy of clinical promotion.